Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis

Evidence-based recommendations for treating persons having presumed latent tuberculosis (LTBI) after contact to infectious multidrug-resistant (MDR) tuberculosis (TB) are lacking because published data consist of small observational studies. Tuberculosis incidence in persons treated for latent MDR -...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Clinical infectious diseases Ročník 64; číslo 12; s. 1670
Hlavní autoři:	Marks, Suzanne M, Mase, Sundari R, Morris, Sapna Bamrah
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 15.06.2017
Témata:	Antitubercular Agents - administration & dosage Antitubercular Agents - economics Antitubercular Agents - therapeutic use Cost-Benefit Analysis Disease Progression Drug Resistance, Multiple, Bacterial - drug effects Ethambutol - economics Ethambutol - therapeutic use Fluoroquinolones - economics Fluoroquinolones - therapeutic use Humans Latent Tuberculosis - drug therapy Latent Tuberculosis - economics Pyrazinamide - economics Pyrazinamide - therapeutic use Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - economics treatment cost contacts tuberculosis multidrug-resistant
ISSN:	1537-6591, 1537-6591
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!